Toxic Keratopathy Associated with Suramin Therapy
- 29 May 1986
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 314 (22), 1455-1456
- https://doi.org/10.1056/nejm198605293142217
Abstract
To the Editor: Suramin, an inhibitor of reverse transcriptase of HTLV-III,1 has been used for many years in the treatment of African trypanosomiasis and onchocerciasis. It now is being used in clinical trials to evaluate its efficacy in patients with AIDS. We have observed a toxic keratopathy possibly due to suramin in these patients.Five patients with AIDS who had no visual symptoms and who were treated with suramin at our institution underwent ophthalmologic evaluations including slit-lamp examinations. All received 500 mg to 1 g of intravenous suramin weekly after an initial dose of 200 mg. Two patients had been . . .Keywords
This publication has 4 references indexed in Scilit:
- Suramin Protection of T Cells in Vitro Against Infectivity and Cytopathic Effect of HTLV-IIIScience, 1984
- Experimental animal model for mucopolysaccharidosis: suramin-induced glycosaminoglycan and sphingolipid accumulation in the rat.Proceedings of the National Academy of Sciences, 1980
- Suramin: With Special Reference to OnchocerciasisPublished by Elsevier ,1978
- Corneal changes in patients treated with clofazimine.British Journal of Ophthalmology, 1976